Leflobakt, 250 mg 10 pcs

Leflobakt^® is a synthetic broad-spectrum antimicrobial bactericidal drug from the group of fluoroquinolones.

Levofloxacin is the left-handed isomer ofloxacin. Levofloxacin blocks enzymes of DNA-enzyme (topoisomerase II) and topoisomerase IV, breaks superspiralization and cross-linking of DNA breaks, causes deep morphological changes in cytoplasm, cell wall and bacterial membrane.

Levofloxacin is active against most strains of microorganisms under both in vitro and in vivo conditions.

Gram-positive aerobic microorganisms: Staphylococcus spp. (coagulazonegative, methicillin-sensitive / moderately methicillin-sensitive strains), Staphylococcus aureus (methicillin-sensitive strains), Staphylococcus epidermidis (methicillin-sensitive strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae (penicillin-sensitive/ moderately penicillin-sensitive/penicillin-resistant strains), Streptococcus spp (groups C, G), Streptococcus viridans (penicillin-sensitive and penicillin-resistant strains), Enterococcus faecalis, Corynebacterium diphtheriae, Listeria monocytogenes.

Gram-negative aerobic microorganisms: Acinetobacter spp. (including Acinetobacter anitratus, Acinetobacter baumannii, Acinetobacter calcoaceticus), Actinobacillus actinomycetemcomitans, Citrobacter freundii, Citrobacter diversus, Eikenella corrodens, Enterobacter spp. Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter cloacae, Enterobacter sakazakii), Escherichia coli, Gardnerella vaginalis, Haemophilus ducreyi, Haemophilus influenzae (ampicillin-sensitive/ampicillin-resistant strains), Haemophilus parainfluenzae, Helicobacter pylori, Klebsiella spp. (including Klebsiella oxytoca, Klebsiella pneumoniae), Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae (including penicillin-producing strains), Neisseria meningitidis, Pasteurella spp. Pasteurella canis, Pasteurella dagmatis, Pasteurella multocida), Proteus mirabilis, Proteus vulgaris, Providencia spp. (including Providencia rettgeri, Providencia stuartii), Pseudomonas spp. (including Pseudomonas aeruginosa, Pseudomonas fluorescens), Salmonella spp, Serratia spp. (including Serratia marcescens).

Anaerobic microorganisms: Bacteroides fragilis, Bifidobacterium spp., Clostridium perfringens, Fusobacterium spp., Peptostreptococcus spp., Propionibacterium spp., Veillonella spp.

Other microorganisms: Bartonella spp, Chlamydia (Chlamydophila) pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Legionella spp. (including Legionella pneumophila), Mycobacterium spp. (including Mycobacterium leprae, Mycobacterium tuberculosis), Mycoplasma hominis, Mycoplasma pneumoniae, Rickettsia spp., Ureaplasma urealyticum.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to levofloxacin:
– Lower respiratory tract (including chronic bronchitis, pneumonia;
– ENT-organ (including sinusitis, otitis media)
– Urinary tract.Lower respiratory tract diseases (including chronic bronchitis, pneumonia);
– ENT-organ diseases (including sinusitis, otitis media);
– of the urogenital organs (including acute pyelonephritis, prostatitis, urogenital chlamydia);
Skin and soft tissue diseases (including infected atherosclerosis).Skin and soft tissues (including infected atheromas, abscesses, furuncles);
In combination therapy of drug-resistant forms of tuberculosis.

Active ingredient

Composition

1 tablet contains levofloxacin (in hemihydrate form) 250 mg.

Auxiliary substances:

Calcium stearate,

Starch 1500,

Potato starch,

Crosspovidone (collidone CL-M),

How to take, the dosage

Leflobact is taken orally, without regard to food intake, 250-500 mg once a day.

The duration of treatment depends on the indications for use.

In case of impaired renal function, adjustment of the regimen of administration is required, including dose reduction according to creatinine clearance.

Contraindications

– epilepsy;
– tendon affection in previous treatment with quinolones;
– impaired renal function in CC – pregnancy;
– lactation period;
– childhood and adolescence under 18 years old;
– hypersensitivity to components of Leflobact.
– The drug should be used with caution in glucose-6-phosphate dehydrogenase deficiency, elderly patients (high possibility of concomitant reduction of renal function).

Side effects

Digestive system disorders: nausea, vomiting, diarrhea (including blood), digestive disorders, decreased appetite, abdominal pain, pseudomembranous enterocolitis, increased liver transaminases activity, hyperbilirubinemia, hepatitis, dysbacteriosis.

Cardiovascular system disorders: decreased BP, vascular collapse, tachycardia, prolongation of QT interval.

Metabolic disorders: hypoglycemia (including increased appetite, increased sweating, trembling).

CNS and peripheral nervous system disorders: headache, dizziness, weakness, drowsiness, insomnia, tremor, anxiety, paresthesia, fear, hallucinations, confusion, depression, motor disorders, epileptic seizures (in predisposed patients).

Sensory organs: disorders of vision, hearing, smell, taste and tactile sensitivity.

Muscular system disorders: arthralgia, muscle weakness, myalgia, tendon rupture, tendinitis, rhabdomyolysis.

Urinary system disorders: hypercreatininemia, interstitial nephritis, acute renal failure.

Hematopoietic system disorders: eosinophilia, hemolytic anemia, leukopenia, neutropenia, agranulocytosis, thrombocytopenia, pancytopenia, hemorrhages.

Allergic reactions: itching and hyperemia of the skin, edema of the skin and mucous membranes, urticaria, erythema malignant exudative (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell syndrome), bronchospasm, choking, anaphylactic shock, allergic pneumonitis, vasculitis.

Others: asthenia, exacerbation of porphyria, photosensitization, persistent fever, development of superinfection.

Similarities